Recently, a novel prognostic biomarker, the Cancer-Inflammation Prognostic Index (CIPI), combined with neutrophil, lymphocyte, and CEA levels, has been reported to be an effective predictor of the prognosis of patients with CRC19. This evidence concerns the gene CEACAM5 and cancer.